Much of the interest in Zomedica has been around the pending release of its Truforma diagnostic software, which is used for the adrenal and thyroid glands on cats and dogs. See all Equities breaking news. Readers are cautioned not to place undue reliance on forward-looking information. About the Zomedica Corp. stock forecast. Reader AdvisoryExcept for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Volume continues surging, and momentum has taken the stock to levels not seen since 2018. Bitcoin sits on the 4-hour SuperTrend, hinting at a possible breakout to $77,000. The initial launch is planned for March, so the clock is now ticking, and speculation is at all-time highs. In theory, Zomedica (NYSEAMERICAN:ZOM) has all the trappings of being, well, a trap.With a market capitalization of $885.03 million, ZOM stock resides around $1. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. Revenue USD Mil Gross Margin percentage Operating Income USD Mil Operating Margin percentage View zom's stock price, price target, earnings, forecast, insider trades nysemkt:zom. US dollar index (DXY) consolidates recent losses around 90.27, down 0.10% intraday, ahead of Tuesday’s European session. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. As previously announced, TRUFORMA can be installed entirely remotely, which should help limit the impact of the COVID-19 pandemic on instrument installations. For more information, visit www.ZOMEDICA.com. Zomedica and its investors prepare for the release of its diagnostic software platform Truforma on March 30th. Moxian's stock was trading at $1.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). A feline-optimized TSH assay is not commercially available. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience and risk appetite. Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™ Certain assays under development are believed to be the … As of 2020 November 17, Tuesday current price of ZOM is $0.00728 and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Zom … As of 2021 February 11, Thursday current price of ZOM stock is 2.320$ and our data indicates that the asset price has been stagnating for the past 1 year (or since … Zomedica Pharmaceuticals Corp. (ZOM) closed the most recent trading day at $0.16, moving +1.31% from the previous trading session. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. See expert views, latest stock price gainers, and much more. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding the public offering. This move outpaced the S&P 500's daily gain of 0.29%. A break above $50,000 may significantly extend the bullish leg above this area, targeting an upswing to $77,000. Since then, OTRK stock has increased by 557.3% and is now trading at $86.57. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. On Friday, Zomedica closed out a turbulent week of trading as the stock lost 3.38% on a day when the major indices posted positive gains. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Now all investors need to wait for is a product. ... of $2.57 which represents gains of over 1,000% in 2021 alone. As far as ZOM stock is concerned, the price is up more than 3,000% since November 3rd last year. ZOM’s stock offering valued at $1.90 per share by its underwriter. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. Zoom stock price forecast for 2021: opportunities and threats. ZOM Stock Forecast. Zomedica believes that the TRUFORMA platform represents the first use of BAW technology in disorder and disease-state diagnostics. The 5 year and 10 year projections for the US stock markets still look promising. ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021. About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. It’s hard to know, but Truforma’s success, or perhaps lack thereof, will be an early indication of how Zomedica’s stock will perform. The stock ended 2020 priced at $0.23 but has since steadily climbed to its closing price on Friday of $2.57 which represents gains of over 1,000% in 2021 alone. The feasibility and design phases of the TRUFORMA ACTH assay have been completed, with verification expected to begin in the near future. Get Our PREMIUM Forecast Now, from ONLY $7.49! ... March 3, 2021: EPS forecast (this quarter) $0.00: Annual revenue (last year) ZOM stock is a speculative buy for several reasons including leaning into a solid, growing market. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). FIBK FORECASTS. The diagnostics segment of the global companion animal market is expected to reach $2.8 billion by 2024 from $1.7 billion in 2019, at a 9.8% CAGR. ZOM is set to launch its Truforma software platform in veterinary offices in March. As of 1:30 p.m. EST, Zomedica's stock … Three months stock forecast Feb. 9, 2021. Find the latest Zomedica Corp. (ZOM) stock quote, history, news and other vital information to help you with your stock trading and investing. Opinions expressed at FXStreet are those of the individual authors and do not necessarily represent the opinion of FXStreet or its management. On the other hand, those riding the price since ZOM flirted with penny-stock territory may want to take profits. Announces Closing of $173.5 Million Bought Deal GlobeNewswire Inc. - 2/11/2021 12:18:17 PM: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/9/2021 5:24:48 PM CLF, ZOM among premarket losers Seeking Alpha - 2/9/2021 8:35:06 AM: Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 2/9/2021 6:08:07 … Maximum value 326, while minimum 290. High volatility in Zomedica Pharmaceuticals Corp stock price on Wednesday which ended trading at $2.55 (Updated on February 10, 2021) Buy or Hold candidate since 2020-11-13 Gain 2 592.71% PDF . The forecast for beginning of March 4.67. I know ZOM will reach $5 by March 30, but what about the rest of the year? Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has signed an agreement with Miller Veterinary Supply (“Miller”) for the distribution of TRUFORMA™, Zomedica’s … The last time the SuperTrend indicator flipped bullish, Bitcoin rallied by nearly 140%. Columbia Sportswear Co - COLM Get email alerts Feb. 9, 2021 SELL. ZOM stock is screaming for the top as retail investors latch on yet again. The initial launch is planned for March, so the clock is now ticking, and speculation is at all-time highs. The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) — a development stage veterinary diagnostic and pharmaceutical company that engages in the discovery, development, and commercialization of pharmaceuticals for pets — is trading at over 45% today as of … What's in Store for Zomedica (ZOM)This Earnings Season? We cannot guarantee future results, performance or achievements. The high degree of leverage can work against you as well as for you. “It certainly is a pleasure to be able to deliver such good news for our shareholders, employees, partners and, especially, the veterinarians whom we serve,” commented Robert Cohen, Interim Chief Executive Officer of Zomedica. Improve your trading results with FXStreet Premium! This assay will enable quantification of samples with low levels of TSH, which is necessary to discriminate normal and hyperthyroid feline samples. Ontrak's stock was trading at $13.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. In doing so, the greenback portrays a corrective pullback from the day’s low while stretching Monday’s downside break of an ascending trend line from January 13. Zom stock price (nyse), score, forecast, predictions, and zomedica pharmaceuticals corp news. Zom stock forecast and score. GBP/USD retreats towards 1.3900 despite upbeat market mood, Bitcoin primed for massive bullish impulse to $77,000, EUR/USD faces rejection at 1.2150 ahead of key data, XAU/USD retreats to session lows, around $1820 area, US Dollar Index: Extends key support break to refresh monthly low. We believe that this will be the first fT4 assay available at the point-of-care. Shares of Zomedica (NYSEMKT:ZOM) soared on Monday, extending the veterinary health company's torrid gains in recent days. Price at the end 308, change for March -4.9%. Most investor focus has been on the company's Truforma diagnostic platform, due to launch in March 2021. When does our forecast turn invalid? Note: All information on this page is subject to change. Price target in 14 days: 4.986 USD. Email Alerts: https://investors.zomedica.com, LinkedIn: https://www.linkedin.com/company/zomedica, Facebook: https://www.facebook.com/zomedica/. Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021. The platform really started to pick up steam when it was announced that Miller Veterinary Supply, the oldest wholesale veterinary distributor in America, would distribute Truforma to veterinary offices. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of our obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Next reporting date: March 2, 2021: EPS forecast (this quarter) $0.79: Annual revenue (last year) $622.7M: Annual profit (last year) $21.8M: Net profit margin To all the Zom Zom Zoms out there. Readers are cautioned that this list of risk factors should not be construed as exhaustive. — Kenny Da Penny Stock Trader (@KennyThePennyS1) January 18, 2021 ZOM discussion on Stocktwits is optimistic. ARCA Biopharma stock predictions for March 2022. Commerce Policy |
Zomedica Corp. All rights reserved. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Mr Clean Commercial 2013,
Tiger Vs Crocodile,
W101 Diamond Farming,
Shark Nv341 Manual,
Scrubblade Discount Code,
Rug Tufting Class Houston,
Oyo Personal Gym,
Homeright Super Finish Max Extra Power Painter,
Married Apostle Joshua Selman Wife Pictures,
How To Find Discord Server,
Letter Repeating Series Questions Pdf,
Cloud For Financial Services,
How Many Guitars Does Taylor Swift Own,